These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 16154853

  • 1. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
    Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB.
    Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
    [Abstract] [Full Text] [Related]

  • 2. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 3. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD, Madueme HL, Wolf RC, Tefferi A.
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [Abstract] [Full Text] [Related]

  • 4. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 5. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
    Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R.
    Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
    D'Arena G, Califano C, Annunziata M, Tartarone A, Capalbo S, Villani O, Amendola G, Pietrantuono G, Ferrara F, Pinto A, Musto P, D'Arco AM, Cascavilla N.
    Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
    [Abstract] [Full Text] [Related]

  • 7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 8. Rituximab in the treatment of autoimmune haematological disorders.
    Garvey B.
    Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
    [Abstract] [Full Text] [Related]

  • 9. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
    Raj K, Narayanan S, Augustson B, Ho A, Mehta P, Duncan N, Tauro S, Mahendra P, Craddock C, Mufti G.
    Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
    [Abstract] [Full Text] [Related]

  • 10. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    D'Arena G, Laurenti L, Capalbo S, D'Arco AM, De Filippi R, Marcacci G, Di Renzo N, Storti S, Califano C, Vigliotti ML, Tarnani M, Ferrara F, Pinto A.
    Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
    [Abstract] [Full Text] [Related]

  • 11. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases.
    Dufour JF, Pradat P, Ruivard M, Hot A, Dumontet C, Broussolle C, Trepo C, Sève P.
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):245-53. PubMed ID: 19279468
    [Abstract] [Full Text] [Related]

  • 12. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.
    Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C.
    Haematologica; 2004 Sep; 89(9):ECR34. PubMed ID: 15377486
    [Abstract] [Full Text] [Related]

  • 13. Combined autoimmune cytopenias.
    Martino R, Muñiz-Díaz E, Arilla M, Ibáñez M, Altés A, Guanyabens C, Madoz P.
    Haematologica; 1995 Sep; 80(4):305-10. PubMed ID: 7590498
    [Abstract] [Full Text] [Related]

  • 14. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
    Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, Díaz-Mediavilla J, Bustelos R, Fernández-Aceñero MJ, Cabrera JR, Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA.
    Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
    [Abstract] [Full Text] [Related]

  • 15. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
    Ramanathan S, Koutts J, Hertzberg MS.
    Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
    Bussone G, Ribeiro E, Dechartres A, Viallard JF, Bonnotte B, Fain O, Godeau B, Michel M.
    Am J Hematol; 2009 Mar; 84(3):153-7. PubMed ID: 19123460
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibodies in the treatment of autoimmune cytopenias.
    Robak T.
    Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
    [Abstract] [Full Text] [Related]

  • 18. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 19. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
    Rodella E, Pacquola E, Bianchini E, Ramazzina E, Paolini R.
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
    [Abstract] [Full Text] [Related]

  • 20. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.